Theriva Biologics, Inc.·4

Feb 3, 6:02 AM ET

SHALLCROSS STEVEN A 4

4 · Theriva Biologics, Inc. · Filed Feb 3, 2023

Insider Transaction Report

Form 4
Period: 2023-02-02
SHALLCROSS STEVEN A
DirectorCEO and CFO
Transactions
  • Purchase

    Common Stock

    2023-02-02$0.94/sh+25,000$23,513185,000 total
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.9349 through $0.9499, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Documents

1 file
  • 4
    tm235343-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT